Clinical trials: Cancer of Pancreas
Pancreatic Cancer
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: FOLFIRINOX which is made up of 4 different drugs: 5-Fluorouracil (5-FU)…
- Trial name
- NCT03563248
- Testing
- FOLFIRINOX, Losartan, Nivolumab
- Where
- 10 sites in United States
- Volunteers
- 168 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Cancer
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
This is a phase II study of biweekly (every other week) bevacizumab followed by gemcitabine then infusional 5-fluorouracil in patients with stage III or IV pancreatic cancer.
- Trial name
- NCT00417976
- Testing
- Gemcitabine, Bevacizumab, Infusional 5-Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Tony Bekaii-Saab
Exocrine Pancreatic Insufficiency (EPI)
Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer
Exocrine pancreatic insufficiency (EPI) is a condition where the pancreas does not have enough pancreatic enzymes to break down food.
- Trial name
- NCT04315311
- Testing
- CREON
- Sponsor
- AbbVie
Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
Treatment, Prospective, Assignment, Open Label, Single-center, Non-randomized Study An exploratory clinical trial of comparison of Nab-Paclitaxel combined with Gemcitabine and Gemcitabine combined with Tegafur for adjuvant…
- Conditions
- Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma, Stage IIB Pancreatic Adenocarcinoma
- Trial name
- NCT04216758
- Testing
- nab-paclitaxel, Gemcitabine, tegafur
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe…
- Conditions
- Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
- Trial name
- PANGEA (NCT06483555)
- Testing
- Gemcitabine, Nab paclitaxel, Erlotinib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell…
- Conditions
- Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT01282333
- Testing
- gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.
- Trial name
- NCT03627390
- Testing
- BP-C1, BP-C2
- Where
- Egypt
- Volunteers
- 16 people
- Sponsor
- Meabco A/S
Pancreatic Cancer, Cholangiocarcinoma
MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers
pancreatic or biliary-tract cancer can be a serious diagnosis, as many patients present too late for surgery. Cancer cells have been found to release small messenger molecules called that regulate cancer genes called microRNAs…
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Ampullary Cancer, Biliary Stricture
- Trial name
- MIRABILE (NCT06258824)
- Testing
- Small RNA Sequencing and Validation of candidate miRNAs
- Where
- United Kingdom
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pancreas Cancer, Pancreatic Ductal Adenocarcinoma
Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening
Software "Lipidica" is intended to be used for processing data generated by the in-house in vitro diagnostic medical device for lipidomic testing for the purpose of screening Pancreatic cancer (PaC) in the population at high risk…
- Conditions
- Pancreas Cancer, Pancreatic Ductal Adenocarcinoma, Hereditary Diseases, Pancreatitis, Chronic
- Trial name
- NCT06549725
- Testing
- software Lipidica, endoscopic ultrasonography, magnetic resonance
- Where
- 16 sites in Czechia
- Volunteers
- 419 people, healthy volunteers welcome
- Sponsor
- Lipidica, a.s.
Pancreatic Cancer
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.
- Trial name
- NCT06601010
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Peritoneal Neoplasms
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally…
- Trial name
- NCT00666991
- Testing
- nanoparticulate paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- CritiTech, Inc.
Pancreas Cancer
Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)
Efficacy and safety of a supportive treatment with European mistletoe extract Iscador® Qu ("quercus", i.e. from oak tree) in patients with pancreatic cancer (Union for International Cancer Control, UICC stages II-IV), in addition…
- Trial name
- NCT01448668
- Where
- 9 sites in Austria, Germany
- Volunteers
- 220 people
- Sponsor
- IFAG AG
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Pancreatic Ductal Carcinoma
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with…
- Trial name
- NCT02715804
- Testing
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), nab-Paclitaxel, Gemcitabine
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 492 people
- Sponsor
- Halozyme Therapeutics
Pancreatic Ductal Adenocarcinoma (PDAC)
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
The proposal aims at determining whether liquid biopsy approaches are valid in the diagnosis of pancreatic cancer. Step1 will test 3 CTC isolation methods and analyse by flow cytometry the presence of onco-exosomes in the culture…
- Trial name
- PANC-CTC (NCT03032913)
- Testing
- Blood samples, Portal vein blood sample
- Where
- France
- Volunteers
- 52 people
- Sponsor
- University Hospital, Bordeaux
Obstructive Jaundice, Pancreatic Head Cancer
Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice
Pancreaticoduodenectomy (PD) is a complex surgical procedure commonly performed for tumors of the pancreatic head and periampullary region.
- Conditions
- Obstructive Jaundice, Pancreatic Head Cancer, Periampullary Neoplasms, Biliary Tract Neoplasms
- Trial name
- NCT07532759
- Testing
- PTCD Catheter Removal, PTCD Catheter Retention
- Volunteers
- 100 people
- Sponsor
- Xu'an Wang
Pancreatic Cancer
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
This study aims to conduct a large-scale prospective clinical trial to evaluate the efficacy and safety of capecitabine monotherapy as maintenance treatment following standard adjuvant chemotherapy (gemcitabine plus capecitabine)…
- Trial name
- NCT07054879
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00024427
- Testing
- fluorouracil, gemcitabine hydrochloride, triacetyluridine
- Where
- 29 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Wellstat Therapeutics
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Trial name
- PILLAR (NCT01836432)
- Testing
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation
- Where
- 32 sites in United States
- Volunteers
- 302 people
- Sponsor
- NewLink Genetics Corporation